Shire Income Statement | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Shire PLC

Shire PLC | Income Statement

Fiscal year is January-December. All values GBP Millions.

2013

2014

2015

2016

2017

2018

2019

Sales/Revenue

3,157

3,657

4,200

8,446

11,772

1,770,531

2,097,224

Cost of Goods Sold (COGS) incl. D&A

584

807

1,021

3,800

5,201

621,664

854,382

Gross Income

2,573

2,850

3,179

4,647

6,571

1,148,867

1,242,842

SG&A Expense

1,486

1,550

1,748

3,204

3,940

953,547

1,060,985

EBIT

1,087

1,300

1,431

1,443

2,631

195,320

181,857

Unusual Expense

671

511

782

662

115,885

125,887

Non Operating Income/Expense

179,418

144,115

Interest Expense

341

446

12,731

68,181

Pretax Income

1,083

2,026

907

360

1,470

217,205

94,896

Income Tax

178

1,831

30,497

14,118

Equity in Affiliates

Consolidated Net Income

908

1,994

875

447

3,303

186,708

109,014

Net Income

908

1,994

875

447

3,303

186,886

109,126

Net Income After Extraordinaries

1,391

1,919

898

652

3,289

186,886

109,126

Net Income Available to Common

426

2,068

853

243

3,317

186,886

109,126

EPS (Basic)

0.77

3.52

1.44

0.32

3.66

239.35

113.50

Basic Shares Outstanding

552

587

590

770

907

781

961

EPS (Diluted)

0.75

3.50

1.44

0.31

3.64

237.55

112.86

Diluted Shares Outstanding

590

591

593

776

912

787

967

EBITDA

1,266

1,547

1,848

2,530

4,389

377,447

454,303

Non-Operating Interest Income

3,282

6,619

About Shire

View Profile

Address	4-1-1 Dosho-machi Osaka Osaka 540 Japan
Employees	-
Website	http://www.takeda.co.jp
Updated	07/08/2019
Shire Plc is a biopharmaceutical company. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet significant unmet patient needs. The company's products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr and foznol.